CBFB and acute myeloid leukemia: Our study indicated that elderly and secondary patients carried more inferior molecular events such as KMT2A‐AF9 and DNMT3A mutations and less favorable ones including RUNX1‐RUNXT1T1, CBFβ‐MYH11, and biallelic CEBPA. Furthermore, genetic aberrations including NRAS, DNMT3A, IDH1 mutations, and CBFβ‐MYH11 conveyed prognostic information independently in e‐AML or s‐AML patients.